Pharma DECODED
Previous edition: 16 Apr 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
FDA grants orphan drug status to NovelMed's PNH treatment
The investigational drug completed a Phase I clinical trial in healthy volunteers with a good safety profile.
NovelMed has announced the receipt of orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational drug, NM5072, for treating paroxysmal nocturnal hemoglobinuria (PNH).
An alternative pathway blocker anti-properdin antibody, NM5072 selectively hinders the immune system components responsible for the disease, inhibiting alternative pathway cascades and preventing the lysis of PNH red blood cells (RBCs).
By blocking the function of properdin, NM5072 prevents the breakdown of PNH RBCs, which is central to the anaemia associated with PNH.
The drug has concluded a Phase I clinical trial in 48 healthy volunteers with a good safety profile.
It is currently being reviewed for multiple indications by regulators in the US and internationally.
PNH is a rare disease characterised by chronic inflammation and haemolysis, in which PNH RBCs break down within and outside blood vessels, leading to anaemia and severe health implications.
NM5072, with its longer half-life, represents a significant advancement in the biologic treatment of PNH to improve patient outcomes.
NovelMed CEO Dr Rekha Bansal stated: “PNH is a rare disease that involves a range of blood cells that contribute to debilitating symptoms for patients, including anaemia, fatigue and severe pain with a shorter life span if it remains untreated.
“We are hopeful that NM5072, with its unique mechanism of action that targets the top of the complement cascade, could become a promising treatment to improve outcomes in these patients.”
The FDA's ODD provides benefits including seven years of market exclusivity upon the receipt of approval, tax credits for clinical trial costs, fee waivers, reduced annual product fees, assistance for clinical protocol development and the possibility of expedited development programmes.
Latest news
Soligenix bags orpan drug designation for Marburg virus vaccine
Soligenix’s Marburg virus vaccine demonstrated 100% protection in non-human primates in a clinical study.
FDA halts Neumora's schizophrenia drug trial over convulsions in rabbits
The FDA placed the clinical hold based on the preclinical data that showed that Neumora’s NMRA-266 triggered convulsions in rabbits.
Novartis reports data from trial of IgA nephropathy treatment
Fabhalta demonstrated significant proteinuria reduction in IgAN patients during the trial.
Pulmocide's inhaled antifungal shows promise in lung transplant patients
Pulmocide has said that opelconazole was also well tolerated with just two discontinuations in the Phase II trial.
Portage mulls company closure, pauses enrolment for lead clinical programme
To extend cash reserves, Portage is exploring numerous strategic alternatives including asset sales, mergers, restructuring and company wind-down.
Marinus fails to meet early stopping criteria for status epilepticus trial
The future development of IV ganaxolone will be determined by results from the Phase III RAISE study, expected in summer 2024.
Sanofi advances NK cell engager to Phase II for blood cancer treatment
The asset is part of a research collaboration and license agreement with Innate Pharma.
In our previous edition
Pharma Decoded
FDA approves new administration routes for Xcopri
15 Apr 2024
Pharma Decoded
Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase
12 Apr 2024
Pharma Decoded
Novartis plans to axe 680 employees
11 Apr 2024
Newsletters in other sectors
Aerospace, Defence & Security
Banking & Payments
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer